Experts Answer FAQs on Immunotherapy for Non-Small-Cell Lung Cancer

In this podcast episode, Julie Brahmer, MD, MSc, and Jarushka Naidoo, MB BCH BAO, MHS, answer audience questions from a live CCO webinar on evolving immunotherapy strategies for NSCLC, with topics including:

• Patient and/or disease-related factors considered when choosing first-line immunotherapy-based regimens
• Second-line therapeutic options after disease progression on an immunotherapy-based regimen
• Immunotherapy in patients with advanced NSCLC and brain metastases
• Distinguishing between immunotherapy-induced and radiation-induced pneumonitis, with expert perspective on rebiopsy
• Future directions in immunotherapy for NSCLC, including the role of the gut microbiome in response

Presenters:

Julie Brahmer, MD, MSc
Professor of Oncology
Director, Thoracic Oncology
Co-Director, Upper Aerodigestive Cancer Program
Bloomberg-Kimmel Institute for Cancer Immunology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins Medicine
Baltimore, Maryland

Jarushka Naidoo, MB BCH BAO, MHS
Consultant Medical Oncologist
Beaumont Hospital/RCSI University of Health Sciences
Dublin, Ireland
Adjunct Assistant Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Content based on an online CME program supported by educational grants from Bristol-Myers Squibb; Genentech, a member of the Roche Group; Helsinn Healthcare SA; and Merck Sharp & Dohme Corp.

Follow along with the PDF:
https://bit.ly/31aRRmd

Link to full program:
https://bit.ly/3CLC0Hd